OBJECTIVE
Peripheral blood CD34
+ cells from diabetic patients demonstrate reduced vascular reparative function due to decreased proliferation and diminished migratory prowess, largely resulting from decreased nitric oxide (NO) bioavailability. The level of TGF-β, a key factor that modulates stem cell quiescence, is increased in the serum of type 2 diabetic patients. We asked whether transient TGF-β1 inhibition in CD34
+ cells would improve their reparative ability.
RESEARCH DESIGN AND METHODS
To inhibit TGF-β1 protein expression, CD34
+ cells were treated ex vivo with antisense phosphorodiamidate morpholino oligomers (TGF-β1-PMOs) and analyzed for cell surface CXCR4 expression, cell survival in the absence of added growth factors, SDF-1-induced migration, NO release, and in vivo retinal vascular reparative ability.
RESULTS
TGF-β1-PMO treatment of diabetic CD34
+ cells resulted in increased expression of CXCR4, enhanced survival in the absence of growth factors, and increased migration and NO release as compared with cells treated with control PMO. Using a retinal ischemia reperfusion injury model in mice, we observed that recruitment of diabetic CD34
+ cells to injured acellular retinal capillaries was greater after TGF-β1-PMO treatment compared with control PMO–treated cells.
CONCLUSIONS
Transient inhibition of TGF-β1 may represent a promising therapeutic strategy for restoring the reparative capacity of dysfunctional diabetic CD34
+ cells.Bone marrow derived progenitor cells (BMPCs) support vascular repair postnatally by direct integration into blood vessels and by the release of paracrine factors such as vascular endothelial cell growth factor, matrix metalloproteases, and angiopoietins to the neovessels (
1,
2). BMPCs possess dramatic ability to revascularize areas within 6–12 h after the injury (
3), accounting for total 1–12% of the endothelial cells present in blood vessels (
4). Lineage negative (lin
−) cells from mice that express the cell surface antigens Sca-1 (Ly-6A/E) and c-kit can develop into endothelium, as can human lin
− cells expressing surface CD34 (
1,
5). Treatment with CD34
+ cells presents an important therapeutic option for revascularization of ischemic vascular areas (
6) and has been successful in numerous clinical trials (
7,
8).However, diabetes significantly impairs the vasoreparative ability of CD34
+ cells. Diabetic patients with peripheral vascular disease have decreased levels of CD34
+ cells and suffer poor vessel growth in response to ischemia (
9); this defect is linked to reduced precursor cell function (
10). The widespread vasodegeneration seen in diabetic retinopathy may be attributed to the inability of BMPCs to compensate for the increased endothelial injury associated with diabetes. In particular, the diabetic BMPCs are unable to repair retinal vasculature (
11); thus, the total rate of retinal cell loss greatly exceeds the reparative function of these cells. We showed that diabetic CD34
+ cells fail to revascularize areas of retinal vascular injury (
11) likely due to reduced migration. Diabetic peripheral neuropathy further hampers repair due to defects of circadian release of BMPCs from the bone marrow, creating an imbalance between the demand and supply of BMPCs during the vasodegenerative stage of diabetic retinopathy (
12). Pharmacological manipulation of diabetic CD34
+ cells (
13) can serve as an important therapeutic strategy for their use as autologous cell therapy to facilitate vascular repair.Transforming growth factor-β1 (TGF-β1) is a pleiotropic factor that regulates the balance between proliferation, differentiation, and quiescence of hematopoietic stem cells (HSCs), both as an extracellular and intracellular ligand (
14,
15). TGF-β1 is elevated in the serum of diabetic patients and possibly intracellularly in CD34
+ cells (
16). Enhanced levels of endogenous TGF-β1 have been reported in peripheral blood mononuclear cells of patients with diabetic nephropathy (
17), and its increase provides a novel mechanism of cellular injury related to elevated glucose levels (
18). Increased levels of TGF-β1 induce cellular senescence and growth arrest (
19). Using blocking antibodies, we showed that transiently inhibiting TGF-β1 in murine HSCs promoted survival of these cells in the absence of growth factors (
20).In this study, we investigated the effect of transient inhibition of endogenous TGF-β1 in peripheral blood diabetic CD34
+ cells using ex vivo treatment with phosphorodiamidate morpholino oligomers (PMOs). PMOs act by stearic inhibition of protein synthesis by high affinity binding to 14–15 contiguous bases. PMOs are highly stable both intra- and extracellularly but are degraded after binding with a half-life of ∼2–4 days in cells (
21). We report here that transient inhibition of TGF-β1 using TGF-β1-PMO may represent a promising therapeutic strategy for restoring vascular reparative function in dysfunctional diabetic CD34
+ cells.
相似文献